Printer Friendly

BIOJECT RELEASES TRANSITIONAL, TWO-MONTH OPERATING RESULTS

 PORTLAND, Ore., May 25 /PRNewswire/ -- Bioject Medical Technologies Inc. (NASDAQ: BJCT), in conjunction with moving its fiscal year from Jan. 31 to March 31, 1993, today announced operating results for the two-month period Feb. 1 through March 31, 1993. As projected, the company reported a loss for the period of $845,000 (9 cents per share), as compared to a loss of $505,000 (6 cents per share) for the same two- month period in 1992.
 Increased expenditures were primarily the result of increased sales, marketing and manufacturing expenses associated with the ramp-up of the recent U.S. launch of the Biojector(R) 2000, a needle-free injection management system. Bioject has in place five area sales managers who coordinate overall U.S. sales of the product, and, as announced on April 15, 1993, significantly expanded its sales and market penetration with the addition of the Alliance Medical, a network of 12 medical specialty distributors employing more than 130 sales representatives nationwide. Training of the distributor sales force commenced in April and will be completed in May. "The members of Alliance Medical have made a significant commitment of their time and resources to selling the Biojector, which underscores their dedication and commitment to its success," stated Richard Hollis, Bioject's chief operating officer.
 The company has targeted hospitals and large clinics as the focus of its initial sales efforts. Bioject management did not anticipate reporting sales during this short, two-month reporting period, due to the length of the sales cycle. However, management expects to report product revenues during the first quarter of the new fiscal year which will be the quarter ending June 30, 1993.
 Revenues increased over the previous year's two-month period primarily due to amounts earned under a continuing joint development agreement with Eli Lilly and Co. Overall expenses were up 89 percent due to sales and marketing expenses associated with the Biojector launch (up $231,000 over the prior period), and also to increased research and development expenses associated with the Lilly agreement ($149,000 over the prior period).
 Bioject is an Oregon corporation dedicated to developing and marketing advanced drug delivery systems using needle-free jet injection technology. Its products dramatically reduce or eliminate the risk of life-threatening needlestick injuries to healthcare workers and their patients that could result in the transmission of bloodborne pathogens (including hepatitis B and AIDS).
 -0- 5/25/93
 /CONTACT: Dan Zenka, APR, or Tim Justice of Bioject, 503-639-7221/
 (BJCT)


CO: Bioject Medical Technologies Inc. ST: Oregon IN: MTC SU: ERN

SW-AL -- SE005 -- 2140 05/25/93 11:54 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 25, 1993
Words:426
Previous Article:FORE SYSTEMS ANNOUNCES MAXIMUM PERFORMANCE SUN SBUS ATM COMPUTER INTERFACE
Next Article:CULP PROJECTS HIGHER FOURTH QUARTER EARNINGS
Topics:


Related Articles
BIOJECT EXPANDS PRODUCT DISTRIBUTION WITH NATIONAL NETWORK
BIOJECT ANNOUNCES FISCAL 1993 OPERATING RESULTS AND NEW FISCAL YEAR END
BIOJECT ANNOUNCES RESULTS FOR THIRD QUARTER FISCAL 1994
BIOJECT AND GIV SIGN EXCLUSIVE DISTRIBUTION AGREEMENT; THREE-YEAR EFFORT TO TARGET OFFICE-BASED PHYSICIAN MARKET
BIOJECT PRODUCT SALES INCREASE IN FISCAL 1995
BIOJECT REPORTS THIRD QUARTER RESULTS AND SUSPENSION OF HMI SHIPMENTS
Bioject Management Comments on Stock Trading/Provides Update
Bioject Reports Improved Fiscal 1997 Performance
Bioject Enters Vaccine Agreement With Merck

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters